Replimune Group, Inc.
NASDAQ:REPLBiotechnology
+$0.19 today
- Market cap
- $1.88B
- Beta
- 0.91
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.42
Volume 2.13M
Average 7.51M
REPL Purchases of Investments
Cash used to buy marketable securities and other investments.
Replimune Group, Inc.NASDAQ: REPL
Purchases of Investments · Q3 FY2026 · quarter ended Dec 2025
Purchases of investments declines year over year
Q3 FY2026 purchases of investments of $26.51M (cash outflow) fell 80.7% year over year, behind the -66.9% change in trailing-twelve-month purchases of investments. Sequentially, it rose 169.2% from the prior quarter. Over 3 fiscal years it compounded at +16.4% a year.
Context
- Purchases of investments grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -80.7% toward the trailing-twelve-month pace of -66.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (403.59M) USD
- Year-over-year change
- +17.6%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | (403.59M) | +17.6% |
| FY2024 | 2024-03-31 | (489.52M) | +16.1% |
| FY2023 | 2023-03-31 | (583.41M) | -128.1% |
| FY2022 | 2022-03-31 | (255.72M) | +34.8% |
| FY2021 | 2021-03-31 | (392.43M) | — |
Purchases of Investments vs competitors
How REPL compares with its peers on the latest reported figures
- REPL's LTM Dec 2025 purchases of investments of $145.57M is the 8th largest of the 11 companies compared; the peer median is $313.75M.
- Its year-over-year change of -66.9% is the lowest of 8, against a peer median of +24.6%.
- Over three fiscal years its annual growth of +16.4% compares with a peer median of +14.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $604.34M | +4.3% | +23.9% | 86.1% | |
| LTM Sep 2026 | $468.45M | +132.1% | — | 256.6% | |
| LTM Mar 2026 | $446.68M | -32.7% | +33.8% | 2066.7% | |
| LTM Sep 2026 | $432.32M | +24.6% | +9.0% | 114.1% | |
| LTM Mar 2026 | $395.83M | +125.8% | — | 1113.7% | |
| LTM Mar 2026 | $231.67M | -37.6% | -13.9% | 747325.8% | |
| LTM Mar 2026 | $202.4M | +485.0% | +20.0% | 128.9% | |
| LTM Dec 2025 | $145.57M | -66.9% | +16.4% | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Dec 2025 | $0 | — | +7.7% | 0.0% | |
| LTM Jun 2024 | $0 | — | — | 0.0% | |
| Peer median (excluding REPL) | $313.75M | +24.6% | +14.5% | 121.5% | |
Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Net Income | (80.87M) | (118.04M) | (174.28M) | (215.79M) | (247.3M) |
| Depreciation & Amortization | 1.71M | 2.15M | 2.45M | 2.66M | 3.5M |
| Deferred Income Tax | 0 | 0 | 38K | 0 | 0 |
| Stock-Based Compensation | 11.79M | 24.25M | 28.13M | 34.13M | 35.04M |
| Change in Working Capital | 3.51M | 7.24M | 15.12M | 5.48M | 24.08M |
| Accounts Receivables | 325K | (247K) | (61K) | (1.92M) | 1.3M |
| Inventory | 0 | 247K | 61K | 0 | 0 |
| Accounts Payables | (1.03M) | 1.12M | 1.98M | (2.79M) | 9.94M |
| Other Working Capital | 4.22M | 6.12M | 13.14M | 10.19M | 12.84M |
| Other Non-Cash Items | 2.47M | 2.22M | 494K | (11.94M) | (7.58M) |
| Operating Cash Flow | (61.39M) | (82.18M) | (128.05M) | (185.47M) | (192.25M) |
| Capital Expenditures | (2.39M) | (2.34M) | (2.27M) | (5.66M) | (6.69M) |
| Acquisitions (Net) | 0 | (530) | 140.23K | 0 | 0 |
| Purchases of Investments | (392.43M) | (255.72M) | (583.41M) | (489.52M) | (403.59M) |
| Sales of Investments | 206.05M | 256.25M | 443.18M | 592.38M | 386.48M |
| Other Investing Activities | 0 | 530 | (140.23K) | 0 | 0 |
| Investing Cash Flow | (188.78M) | (1.81M) | (142.5M) | 97.2M | (23.8M) |
| Debt Repayment | (10.15M) | (264K) | 27.79M | 14.52M | (599K) |
| Common Stock Issued | 286.11M | 6.86M | 187.29M | 1.76M | 155.73M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 96.5M | 0 | 96.22M | 0 | 97.27M |
| Financing Cash Flow | 372.46M | 6.6M | 311.3M | 16.28M | 252.4M |
| Effect of Forex Changes | 721K | 818K | (109K) | (86K) | 315K |
| Net Change in Cash | 123.02M | (76.57M) | 40.64M | (72.07M) | 36.67M |
| Free Cash Flow | (63.78M) | (84.52M) | (130.32M) | (191.13M) | (198.94M) |
Replimune Group, Inc.
NASDAQ:REPL
Intrinsic Alpha fair value
Locked
Current Price
$19.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.